CVD: risk assessment and reduction, including lipid modification.


Information Sharing Event 17<sup>th</sup> April 2023





## Purpose of today's event

- To provide an overview of work to:
  - Update NICE guideline CG181 (Cardiovascular disease: risk assessment and reduction, including lipid modification)
  - Develop an indicator on treatment target (s) for secondary prevention
- To describe the approach being taken to this work
- To share the key dates and timelines for stakeholders to engage with consultation
- Opportunity for questions.



#### NICE staff in attendance

- Eric Power Programme Director (chair)
- Bhash Naidoo Senior Technical Adviser, Health Economics
- Catrina Charlton Guideline Commissioning Manager
- Mark Minchin Associate Director
- Jasdeep Hayre Associate Director, Health Technology Assessment [industry event only]
- Craig Grime Technical Adviser
   NICE National Institute for
   Health and Care Excellence

### NICE guideline on CVD May 2023 update



- What is the most effective risk assessment tool?
- Lifestyle modifications for the primary and secondary prevention of CVD
- Statin therapy for the primary and secondary prevention of CVD



• Consultation on draft recommendations - 12<sup>th</sup> Jan 2023 to 2<sup>nd</sup> Feb 2023



• Final guidance expected – 17<sup>th</sup> May 2023

### NICE guideline on CVD September 2023 update



• In people with established cardiovascular disease, when and to what target should lipid modification therapy be escalated?



 Consultation on draft recommendations <u>and</u> draft indicator <u>22<sup>nd</sup> June 2023 to 5<sup>th</sup> July 2023</u>



• Final guidance expected – 22<sup>nd</sup> September 2023

## Lipid modification NICE indicator treatment target, secondary prevention



- An indicator underpinned by NICE guidance that can be used in the QOF
- Likely incorporate a non-HDL cholesterol and LDL-cholesterol option



• Consultation on draft indicator - 22<sup>nd</sup> June 2023 to 5<sup>th</sup> July 2023



• Final indicator expected – 22<sup>nd</sup> September 2023

## Treatment target for secondary prevention Review protocol

#### Appendix A: Review protocol


Review protocol for escalation of lipid modification therapy for secondary prevention of cardiovascular disease (CVD)

Field	Content
Review title	Escalation of lipid modification therapy for secondary prevention of CVD
Review question	In adults with CVD requiring escalation of therapy beyond statins, what is the effectiveness of lipid- lowering therapy?
Objective	To provide evidence on lipid lowering, CVD event risk reduction achieved, and adverse events experienced during escalation of lipid modification therapy to support the identification of a target for secondary prevention of CVD.
	This review will not be considering sequencing of treatment options listed in the interventions.
Searches	Key papers:  • IMPROVE-IT  • FOURIER  • ODYSSEY OUTCOMES  • ORION-10 and -11
	Cochrane review on Ezetimibe Cochrane review on PCSK9 monoclonals  The following databases will be searched: Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Database of Systematic Reviews (CDSR) Embase MEDLINE Epistemonikos
	Review title Review question Objective

5.	Condition or domain being studied	Cardiovascular disease
6.	Population	Inclusion:  • Adults (aged 18 years and older) with CVD.  ○ Studies that include ≥80% participants with CVD (or presenting subgroup data for those with CVD) will be preferentially included.  ○ If insufficient data are available from CVD populations, studies including mixed populations with and without CVD (50-79% CVD) will be considered for inclusion. This will be decided separately for each comparison.
		CVD is defined as including people with/requiring the following:  Ischaemic stroke  Transient ischaemic attack  Myocardial infarction  Coronary heart disease (for example unstable and stable angina)  Peripheral artery disease  Coronary or non-coronary arterial revascularisation procedures
		Exclusion:  • Children aged under 18 years of age.

# Treatment target for secondary prevention Economic plan

#### List of modelling questions Review Treatment target for secondary prevention: In people with established cardiovascular disease, when and to what target questions by scope area should lipid modification therapy be escalated? Population Adults who have CVD and are on lipid modification treatment with a statin. People whose cholesterol level is above the target despite being Interventions and on a statin will receive further treatments. comparators considered for Different targets for cholesterol (non-HDL or LDL) in primary care inclusion will be compared to identify the ones that are the most costeffective. Perspective NHS and personal social services QALY Outcomes Type of analysis Cost-utility analysis Modelling Excel software Issues to note



## Thank you

© NICE 2023. All rights reserved. Subject to notice of rights.